External Validation of SAFE Score to Predict Atrial Fibrillation Diagnosis after Ischemic Stroke: A Retrospective Multicenter Study

Other authors

Institut Català de la Salut

[Quesada López M, Amaya Pascasio L] Neurology, Hospital Universitario Torrecárdenas, Almería, Spain. [Blanco Madera S] Neurology, Hospital Universitario Virgen de las Nieves, Granada, Spain. [Pagola J, Elosua Bayes I, Lázaro Hernández C] Servei de Neurologia, Vall d’Hebron Hospital Universitari, Barcelona, Spain. [Vidal de Francisco D] Neurology, Hospital Universitario de León, León, Spain. [de Celis Ruiz E] Neurology, Hospital La Paz Institute for Health Research-IdiPaz (La Paz University Hospital-Universidad Autónoma de Madrid, Spain

Vall d'Hebron Barcelona Hospital Campus

Publication date

2024-01-15T13:15:44Z

2024-01-15T13:15:44Z

2023-12-07



Abstract

Diagnóstico; Fibrilación auricular; Ictus isquémico


Diagnòstic; Fibril·lació auricular; Ictus isquèmic


Diagnosis; Atrial fibrillation; Ischemic stroke


Introduction: The screening for atrial fibrillation (AF) scale (SAFE score) was recently developed to provide a prediction of the diagnosis of AF after an ischemic stroke. It includes 7 items: age ≥ 65 years, bronchopathy, thyroid disease, cortical location of stroke, intracranial large vessel occlusion, NT-ProBNP ≥250 pg/mL, and left atrial enlargement. In the internal validation, a good performance was obtained, with an AUC = 0.88 (95% CI 0.84-0.91) and sensitivity and specificity of 83% and 80%, respectively, for scores ≥ 5. The aim of this study is the external validation of the SAFE score in a multicenter cohort. Methods: A retrospective multicenter study, including consecutive patients with ischemic stroke or transient ischemic attack between 2020 and 2022 with at least 24 hours of cardiac monitoring. Patients with previous AF or AF diagnosed on admission ECG were excluded. Results: Overall, 395 patients were recruited for analysis. The SAFE score obtained an AUC = 0.822 (95% CI 0.778-0.866) with a sensitivity of 87.2%, a specificity of 65.4%, a positive predictive value of 44.1%, and a negative predictive value of 94.3% for a SAFE score ≥ 5, with no significant gender differences. Calibration analysis in the external cohort showed an absence of significant differences between the observed values and those predicted by the model (Hosmer-Lemeshow's test 0.089). Conclusions: The SAFE score showed adequate discriminative ability and calibration, so its external validation is justified. Further validations in other external cohorts or specific subpopulations of stroke patients might be required.


We acknowledge FIBAO (Biomedical Research Foundation) and Adrián Aparicio Mota for their assistance with statistical analysis. Adrián Aparicio (a FIBAO statistician) analyzed the collected data. The project was the winner of the IV research grant “STROKE PROJECT 2020” from the Spanish Society of Neurology.

Document Type

Article


Published version

Language

English

Publisher

Hindawi

Related items

Stroke Research and Treatment;2023

https://doi.org/10.1155/2023/6655772

Recommended citation

This citation was generated automatically.

Rights

Attribution 4.0 International

http://creativecommons.org/licenses/by/4.0/

This item appears in the following Collection(s)